Valneva has filed a patent for a polypeptide containing a mutant fragment of an outer surface protein A (OspA) for treating or preventing Borrelia infection. The patent also covers a nucleic acid coding for the polypeptide, a pharmaceutical composition, and methods of treating, preventing, and immunizing against Borrelia infection. GlobalData’s report on Valneva gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Valneva, Anti-viral antigen-based compositions was a key innovation area identified from patents. Valneva's grant share as of September 2023 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Polypeptide for treating or preventing borrelia infection
A recently filed patent (Publication Number: US20230295245A1) describes a polypeptide that could be used for treating or preventing Borrelia infections. The polypeptide is a mutant fragment of a Borrelia outer surface protein A (OspA) and has a sequence identity of at least 95% to a wild-type serotype 2 OspA fragment. The mutant fragment differs from the wild-type fragment by the addition of at least one disulfide bond.
The patent claims also describe different forms of the polypeptide, including heterodimers with specific sequences. These heterodimers are Lip-S1 D1-S2D1, Lip-S2D1-S1D1, Lip-S1D4-S2D1, and Lip-S2D1-S1D4. The polypeptide can be used alone or in a pharmaceutical composition, which may include a pharmaceutically acceptable carrier or excipient. L-methionine and/or aluminum hydroxide are mentioned as possible excipients.
The patent also covers methods of treating or preventing Borrelia infections by administering the polypeptide or the pharmaceutical composition to a subject in need. The Borrelia infections that can be targeted include B. burgdorferi, B. garinii, B. afzelii, B. andersoni, B. bavariensis, B. bissettii, B. valaisiana, B. lusitaniae, B. spielmanii, B. japonica, B. tanukii, B. turdi, and B. sinica.
Additionally, the patent describes a method for producing the polypeptide. This method involves introducing a vector encoding the polypeptide into a host cell, growing the host cell, homogenizing it, and subjecting the homogenate to purification steps. The vector used is pET28b(+) and the host cell is Escherichia coli (E. coli), specifically an E. coli BL21 cell. The purification steps may include enriching the polypeptide in a lipid phase separation, purifying it over a gel filtration column, and processing it over a buffer exchange column.
In summary, the patent describes a mutant fragment of a Borrelia outer surface protein A (OspA) that could be used for treating or preventing Borrelia infections. The polypeptide can be used alone or in a pharmaceutical composition and can be produced using a specific method involving E. coli as the host cell. The patent covers various forms of the polypeptide and methods of administration for treating Borrelia infections caused by different Borrelia species.
To know more about GlobalData’s detailed insights on Valneva, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
